340 results on '"Tai, Yu-Tzu"'
Search Results
2. Author Correction: The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
3. Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
4. UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
5. Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
6. Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
7. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma
8. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma
9. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
10. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma
11. Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
12. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
13. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
14. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma
15. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
16. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
17. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
18. Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
19. Data from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
20. Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
21. Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
22. Supplemental Table S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
23. Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3′-Kinase/AKT Signaling
24. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
25. Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
26. Retraction: Effects of Oligonucleotide N3′→P5′ Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells
27. Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line
28. Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage
29. Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
30. Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
31. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma
32. Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma
33. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
34. Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
35. Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
36. Supplemental Table S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
37. Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
38. Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
39. Data from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
40. Data from Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
41. Supplementary Method from Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
42. Data from Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
43. Data from ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
44. Supplementary Figure S2 from Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
45. Supplementary Methods from ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
46. Supplementary Table S2 from Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
47. Supplementary Figures 1-15, Supplementary Table 1 from ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
48. Supplementary Figure 1-9 from Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
49. Supplementary Table S1 from Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
50. Data from Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.